Results 61 to 70 of about 63,206 (209)

Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B

open access: yesIntervirology, 2021
Introduction: Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments.
Sara Jeong, Hyun Phil Shin, Ha Il Kim
doaj   +1 more source

Evidence-Based Study of Medication Compliance Project in Hiv Prevention Using Pre-Exposure Prophylaxis (Prep) Antivirals for HIV-Negative Males [PDF]

open access: yes, 2018
In 2012, emtricitabine/tenofovir was the only Food and Drug Administration-approved medication for pre-exposure prophylaxis (PrEP) used in human immunodeficiency virus (HIV) prevention.
Ho, Ming-Chun
core   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang   +32 more
wiley   +1 more source

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

open access: yesFrontiers in Pharmacology
ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao   +4 more
doaj   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann   +7 more
wiley   +1 more source

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]

open access: yes, 2019
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A   +11 more
core  

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]

open access: yes, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry   +39 more
core   +3 more sources

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

open access: yesHepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami   +15 more
wiley   +1 more source

Tenofovir induced lichenoid drug eruption

open access: yesAvicenna Journal of Medicine, 2015
Cutaneous adverse reactions are a common complication of anti-retroviral therapy. Tenofovir is a newer anti-retroviral drug belonging to the nucleotide reverse transcriptase inhibitor group.
Mrinal Gupta, Heena Gupta, Anish Gupta
doaj   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

open access: yesHIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy